Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYTOPREV valganciclovir prevention strategy in kidney transplant recipients
2024-515925-27-00Phase 3Authorised
- Sponsor
- Rouen University Hospital
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of valganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by Rouen University Hospital. Primary endpoint: CMV infection within 6 months. Planned start Aug 2024; status: authorised.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2024-515925-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515925-27-00.